235 related articles for article (PubMed ID: 35771147)
1. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma.
Shi R; Zhao H; Zhao S; Yuan H
Aging (Albany NY); 2022 Jun; 14(12):5271-5291. PubMed ID: 35771147
[TBL] [Abstract][Full Text] [Related]
2. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
Zhao J; Liu Z; Yang K; Shen S; Peng J
Front Immunol; 2024; 15():1333923. PubMed ID: 38736884
[TBL] [Abstract][Full Text] [Related]
4. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Yu L; Ji T; Liao W; Xu Y; Fang Y; Zhu Q; Nie J; Yang D
Clin Epigenetics; 2023 Mar; 15(1):43. PubMed ID: 36932439
[TBL] [Abstract][Full Text] [Related]
5. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
6. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
8. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.
Zhang YP; Bao ZW; Wu JB; Chen YH; Chen JR; Xie HY; Zhou L; Wu J; Zheng SS
Technol Cancer Res Treat; 2020; 19():1533033820944274. PubMed ID: 32715976
[TBL] [Abstract][Full Text] [Related]
9. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma.
Zhang G; Lv X; Yang Q; Liu H
BMC Cancer; 2022 Aug; 22(1):888. PubMed ID: 35964022
[TBL] [Abstract][Full Text] [Related]
10. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.
Wang Y; Peng B; Ning C; He S; Yang H; Mao Y; Sun L
Front Immunol; 2022; 13():966167. PubMed ID: 36304466
[TBL] [Abstract][Full Text] [Related]
11. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma.
Xu W; Nie C; Lv H; Chen B; Wang J; Wang S; Zhao J; He Y; Chen X
Front Immunol; 2022; 13():1010554. PubMed ID: 36275697
[TBL] [Abstract][Full Text] [Related]
13. Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma.
Cai J; Wu S; Zhang F; Dai Z
Front Immunol; 2022; 13():952413. PubMed ID: 35911718
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
Yin T; Zhao L; Yao S
BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
[TBL] [Abstract][Full Text] [Related]
15. Integrating transcriptomes and somatic mutations to identify RNA methylation regulators as a prognostic marker in hepatocellular carcinoma.
Yan Y; Luo YH; Zheng DF; Mu T; Wu ZJ
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):34-45. PubMed ID: 32563589
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.
Huang X; Yang C; Wang J; Sun T; Xiong H
Aging (Albany NY); 2020 Mar; 12(6):4970-4995. PubMed ID: 32201399
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer.
Meng Q; Lu YX; Ruan DY; Yu K; Chen YX; Xiao M; Wang Y; Liu ZX; Xu RH; Ju HQ; Qiu MZ
Mol Ther Nucleic Acids; 2021 Jun; 24():695-710. PubMed ID: 33996253
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma.
Ma P; Zou C; Xia S
Immunogenetics; 2022 Dec; 74(6):539-557. PubMed ID: 35895154
[TBL] [Abstract][Full Text] [Related]
20. m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.
Zhou D; Wang Y; Wei W; Zhou W; Gu J; Kong Y; Yang Q; Wu Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3661-3680. PubMed ID: 35972694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
